Phase I Study on the Safety and Tolerability of RA0127 for the Prevention of Gram-negative Bacterial Infections in Healthy Volunteers

The primary objective of this study is to evaluate the **safety** and **tolerability** of single ascending intravenous doses and multiple intravenous doses of RA0127 in healthy young volunteers. This is clinically relevant as it aims to establish the initial safety profile of RA0127, which is intended for the prevention of infections caused by **Gram-negative bacteria**. Understanding the safety and tolerability in a healthy population is a critical step before considering further clinical development in patients at risk of such infections.

The clinical trial focuses on the **prevention of infections** caused by Gram-negative bacteria. The study population includes both male and female participants, with an age range categorized as adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the study. Participants were selected without any disclosed lifestyle considerations such as diet, physical activity, or habits. Key inclusion or exclusion criteria have not been specified by the sponsor.

The clinical trial is designed as a **randomized, double-blind, placebo-controlled** study to evaluate the safety and tolerability of single ascending intravenous doses and multiple intravenous doses of RA0127 in healthy young volunteers. The trial is focused on the **prevention of infections caused by Gram-negative bacteria**. This is a Phase 1 trial, indicating that it is a "first-in-human" study, primarily aimed at assessing the safety profile of the investigational product.

The trial is expected to commence recruitment on September 4, 2023, and is estimated to conclude by January 8, 2024. Participants will be involved in the study for the duration of the trial, with specific timelines for each participant depending on their enrollment date and the dosing schedule. The study will include several key visits: an initial screening visit to determine eligibility, multiple follow-up visits to monitor safety and tolerability, and an end-of-study visit to assess final outcomes and gather comprehensive safety data.

Participants will be randomly assigned to receive either the investigational product or a placebo, with neither the participants nor the investigators aware of the group assignments, ensuring the double-blind nature of the study. The inclusion visit will involve a thorough screening process to confirm that participants meet the eligibility criteria. Follow-up visits will be scheduled at regular intervals to monitor the participants' health status and any adverse events. The end-of-study visit will serve to collect final data and ensure the well-being of the participants post-trial.

Participant involvement is expected to last for the entire duration of the trial unless specific conditions necessitate early termination. Such conditions may include the occurrence of significant adverse events, withdrawal of consent by the participant, or any other protocol-defined criteria that compromise the safety or integrity of the study. The trial's design and procedures are structured to ensure rigorous assessment of the investigational product's safety and tolerability, providing valuable data for future research and development.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety, dosage, and initial efficacy. The trial is scheduled to commence recruitment on September 4, 2023, with an estimated end date of January 8, 2024. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve the collection of preliminary data on the drug's effects, which may include biomarker levels or symptom improvement scores. The methods for measuring and analyzing these parameters are not specified, but they generally involve validated scales or laboratory tests. The trial's efficacy assessments are expected to be conducted at predetermined intervals throughout the study duration, aligning with standard clinical trial practices.